CCR10 and neoplasm: While CCL28 has both anti- and pro-tumor properties, the latter dominate in the hypoxic cancerous Tumor Micro-Environment (TME) and involves stimulating the chemotaxis of myofibroblasts and various lymphocyte types, including Tregs, to the tumor site via CCR10 activation [4-7].